| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/04/2001 | WO2001000650A1 Cytoplasmic transfer to de-differentiate recipient cells |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000619A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | WO2001000616A1 Cholesterol biosynthesis inhibitors containing as the active ingredient aromatic compounds bearing cyclic amino groups |
| 01/04/2001 | WO2001000615A1 Respiratory syncytial virus replication inhibitors |
| 01/04/2001 | WO2001000612A2 Respiratory syncytial virus replication inhibitors |
| 01/04/2001 | WO2001000610A1 Substituted benzimidazole |
| 01/04/2001 | WO2001000603A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/04/2001 | WO2001000589A1 6-carboxyphenyldihydropyridazinone derivatives and use thereof |
| 01/04/2001 | WO2001000587A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 01/04/2001 | WO2001000586A1 Compounds as selective agonists at alpha 2b or 2b/2c adrenergic receptors |
| 01/04/2001 | WO2001000583A1 Ucf116 derivatives as antitumor agents |
| 01/04/2001 | WO2001000578A1 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| 01/04/2001 | WO2001000558A1 Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates |
| 01/04/2001 | WO2001000245A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000243A1 Pharmaceutical complex |
| 01/04/2001 | WO2001000230A1 Drug composition containing lecithin-modified superoxide dismutase |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2001000228A1 Method for preventing tumoral growth |
| 01/04/2001 | WO2001000227A1 Gonadotropin releasing hormone antagonist |
| 01/04/2001 | WO2001000221A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | WO2001000220A2 Lipoprotein lipase (lpl) variant therapeutics |
| 01/04/2001 | WO2001000214A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000213A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2001000207A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000206A1 Vla-4 inhibitor compounds |
| 01/04/2001 | WO2001000203A1 Use of creatine or creatine compounds for skin preservation |
| 01/04/2001 | WO2001000197A2 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 01/04/2001 | WO2001000193A2 Zinc ionophores as anti-apoptotic agents |
| 01/04/2001 | WO2001000183A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 01/04/2001 | WO2001000047A1 Prophylactic dietary supplement based on milk |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000053236A3 Methods and compositions for targeted drug delivery |
| 01/04/2001 | WO2000038715A3 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 01/04/2001 | WO2000031095A3 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | DE19929782A1 6-Carboxyphenyldihydropyridazinon-Derivate und ihre Verwendung 6-Carboxyphenyldihydropyridazinon derivatives and their use |
| 01/04/2001 | CA2727172A1 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 01/04/2001 | CA2435411A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | CA2383546A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2378221A1 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377541A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | CA2377515A1 Cytoplasmic transfer to de-differentiate recipient cells |
| 01/04/2001 | CA2377492A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 01/04/2001 | CA2377438A1 Gene encoding promoter domain of tumor suppressor gene p51 and use thereof |
| 01/04/2001 | CA2377437A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | CA2377287A1 Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates |
| 01/04/2001 | CA2377224A1 Inhibitors of the integrin .alpha.v.beta.6 |
| 01/04/2001 | CA2377186A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | CA2377163A1 Screening methods for compounds that affect melanogenesis |
| 01/04/2001 | CA2377117A1 6-carboxyphenyldihydropyridazinone derivatives and use thereof |
| 01/04/2001 | CA2376957A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376951A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376935A1 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | CA2376920A1 Method for preventing tumoral growth |
| 01/04/2001 | CA2376892A1 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 01/04/2001 | CA2376881A1 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments |
| 01/04/2001 | CA2376785A1 Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | CA2375852A1 Zinc ionophores as anti-apoptotic agents |
| 01/04/2001 | CA2374610A1 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | CA2370500A1 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| 01/04/2001 | CA2370099A1 Bh3 modified peptides |
| 01/04/2001 | CA2370081A1 Lpl variant therapeutics |
| 01/04/2001 | CA2369308A1 Vla-4 inhibitor compounds |
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | CA2365341A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | CA2341974A1 Gonadotropin releasing hormone antagonist |
| 01/03/2001 | EP1065210A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/03/2001 | EP1065209A1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/03/2001 | EP1065208A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/03/2001 | EP1065207A1 Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| 01/03/2001 | EP1065206A1 Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents |
| 01/03/2001 | EP1065204A1 Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors |
| 01/03/2001 | EP1064965A2 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064403A1 Antisense modulation of pecam-1 |
| 01/03/2001 | EP1064371A2 Isolated mammalian membrane protein genes and related reagents |
| 01/03/2001 | EP1064364A1 The cytokine family member 2-21 |
| 01/03/2001 | EP1064356A2 Cardiac-derived stem cells |
| 01/03/2001 | EP1064298A2 Inhibitors of caspases |
| 01/03/2001 | EP1064297A1 95 human secreted proteins |
| 01/03/2001 | EP1064289A1 Heterocyclic signal transduction inhibitors, compositions containing them |
| 01/03/2001 | EP1064284A1 Hypnotic beta-carboline derivatives, process for their preparation and their use as medicinal products |
| 01/03/2001 | EP1064283A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors |
| 01/03/2001 | EP1064277A1 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| 01/03/2001 | EP1064274A1 Benzenesulfonamide derivatives and their use as medicaments |
| 01/03/2001 | EP1064270A2 Disubstituted pyrazolines and triazolines as factor xa inhibitors |
| 01/03/2001 | EP1064269A1 Barbituric acid derivative and preventive and therapeutic agent for bone and cartilage containing the same |
| 01/03/2001 | EP1064263A2 Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection |
| 01/03/2001 | EP1064262A1 Substituted isoindolones and their use as cyclic gmp modulators in medicaments |
| 01/03/2001 | EP1064256A1 Bicyclo [2.2.1] heptanes and related compounds |
| 01/03/2001 | EP1064254A2 Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents |
| 01/03/2001 | EP1064027A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064021A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/03/2001 | EP1064018A2 The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/03/2001 | EP1064017A1 A method for the prevention of a patient's fibroproliferative vasculopathy |